ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

ESMO 2022: Highlights, commentary and analysis

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup

Fruquintinib provides improvement in overall survival for refractory mCRC

ESMO 2022: Breast cancer highlights

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO